This is consistent with observations following aHSCT in refractory Crohn’s Disease and use of anti-TNFα therapy after aHSCT (24) and in rheumatoid arthritis and use of disease-modifying agents after aHSCT (25), where there is renewed sensitivity to drugs associated with the “immune reset” after aHSCT. This evidence concerns the gene TNF and Crohn disease.